About Epocal
Epocal is a company based in Ottawa (Canada) founded in 2001 was acquired by Siemens in July 2017. Epocal has raised $40.51 million across 6 funding rounds from investors including Siemens, Highland Capital and Genesys Capital. Epocal operates in a competitive market with competitors including Daxor, Hemcheck, Cellmic, Essenlix and Chipcare, among others.
- Headquarter Ottawa, Canada
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Epocal
Epocal has successfully raised a total of $40.51M across 6 strategic funding rounds. The most recent funding activity was a Series C round of $31 million completed in April 2007. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Epocal
Epocal has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include Siemens, Highland Capital and Genesys Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early-stage life sciences companies are supported through venture capital investments.
|
Locked | Locked | Locked | |
|
Tech & Life-Sciences focused Growth stage Venture Debt Firm investing in North America
|
Locked | Locked | Locked | |
|
Investment management services are offered by Highland Capital.
|
Locked | Locked | Locked |
Investor details for Epocal
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Epocal
Investment portfolio details for Epocal
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Epocal
Detailed financials for Epocal
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Epocal Comparisons
Peer comparison for Epocal
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Epocal
Epocal operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Daxor, Hemcheck, Cellmic, Essenlix and Chipcare, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Blood volume analyzers are developed by Daxor for diagnostic applications.
|
|
| Locked | Locked | Locked |
Devices for detecting hemolyzed blood samples are provided by Hemcheck.
|
|
| Locked | Locked | Locked |
Rapid test readers are developed for chromatographic and fluorescent assays.
|
|
| Locked | Locked | Locked |
Mobile health self-test platform is provided using nanotechnology and AI.
|
|
| Locked | Locked | Locked |
Develops a hand-held blood test device from a single drop of blood.
|
Detailed competitors of Epocal
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Epocal
Complete news archive for Epocal
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Epocal
Epocal was founded in 2001.
Epocal is headquartered in Ottawa, Canada. It is registered at Ottawa, Ontario, Canada.
Epocal is a funded company, having raised a total of $40.51M across 6 funding rounds to date.
Epocal researches and develops biochips and solid-state diagnostic devices. Epocal is implementing an entire blood diagnostic system in FlexCard technology, a card format similar to the smart card used in conventional check and telephone cards. Epocal manufactures cards at ultra low cost, leveraging already existing high volume low cost production technologies for smart cards. The proprietary FlexCard technology, comprising biosensors and integral fluidics on flex circuit modules in a credit card-sized housing. The companys new enterprise point-of-care blood diagnostic system, the Epoc comprising diagnostic test cards and wireless card readers is intended to be used in all low volume, distributed testing applications, where high sensitivity and lab quality accuracy is required: in hospitals at the bedside, in physicians offices and in patients homes.
Epocal's top competitors include Daxor, Pathshodh Healthcare and Cellmic.
Epocal has 4 investors. Key investors include Siemens, Highland Capital, Genesys Capital, and MMV Financial.